FINWIRES · TerminalLIVE
FINWIRES

Barton Gold Says Drilling at South Australian Gold Project Confirm High-Grade Mineralization

-- Barton Gold Holdings (ASX:BGD) said drilling at its Challenger gold project in South Australia confirm high-grade mineralization in the pit floor at the Challenger West pit, according to a Wednesday Australian bourse filing.

The company encountered intercepts of 7 meters at 2 grams-per-tonne (g/t) grade of gold from surface, as well as 3 meters at 20.6 g/t grade of gold from 13 meters.

The drilling validates previously modeled mineralization, with in-pit materials grading between 5 g/t to 20 g/t grade of gold at shallow depths below the pit floor, and peak assays grading up to 60 g/t grade of gold.

The company's shares fell nearly 1% in recent trading on Wednesday.

Related Articles

Asia

Beijing Enlight Media Q1 Profit Falls 99%; Shares Down 8%

Beijing Enlight Media Co (SHE:300251) posted first-quarter attributable net profit of 23.3 million yuan, down 99% from 2.02 billion yuan the previous year.Earnings per share went down to 0.01 yuan from 0.69 yuan, according to a Wednesday filing with the Shenzhen bourse.Operating revenue fell 94% year over year to 190.6 million yuan from 2.97 billion yuan.Shares of the media company were down 8% in recent trade.

$SHE:300251
Asia

Enlight Media 2025 Profit Jumps 473%; Shares Fall 7%

Beijing Enlight Media (SHE:300251) posted 2025 attributable net profit of 1.67 billion yuan, up 473% from 292.0 million yuan the previous year.Earnings per share went up to 0.57 yuan from 0.10 yuan, according to a Wednesday filing with the Shenzhen bourse.Operating revenue jumped 155% year over year to 4.04 billion yuan from 1.59 billion yuan.Shares of the media company were down 7% in recent trade.

$SHE:300251
Asia

CR Double-Crane Pharma Gets Nod to Name Unit as Marketer of Endometriosis Drug

China Resources Double-Crane Pharmaceutical (SHA:600062) received approval from the National Medical Products Administration to change the marketing authorization holder of dienogest tablets, according to a Shanghai bourse filing on Wednesday.Under the approved supplementary application, the pharmaceutical company's subsidiary, CR Zizhu Pharmaceutical, becomes the marketing authorization holder, as well as the manufacturer of the endometriosis drug.

$SHA:600062